November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
pCR rates for patients with HR+/HER2 breast cancer – Annals of Oncology
Oct 31, 2024, 14:59

pCR rates for patients with HR+/HER2 breast cancer – Annals of Oncology

Annals of Oncology shared a post on X about a recent paper by L.A. Huppert et al. published in Annals of Oncology.

“New in press: Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.”

Paolo Tarantino shared this post, adding:

Great work Laura Huppert, Hope Rugo and I-SPY2 team!”

“Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial”

Authors: L.A. Huppert, D. Wolf,  C. Yau, L. Esserman, H.S. Rugo et al.

pCR rates for patients with HR+/HER2 breast cancer - Annals of Oncology

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.

More posts featuring Annals of Oncology.